Plus Therapeutics, INC DEF 14A proxy statements

Plus Therapeutics, Inc. outlines its 2026 strategic plan for CNS cancer therapeutics and diagnostics, alongside proposals for its Annual Meeting including director elections and a significant stock incentive plan amendment.

Plus Therapeutics, Inc. filed a supplement to its definitive proxy statement to correct an inadvertent error regarding the voting standard for its Reverse Stock Split Proposal.

Plus Therapeutics, a biotechnology company focused on CNS cancers, is seeking shareholder approval for a significant capital raise and a reverse stock split to address Nasdaq listing compliance while advancing its radiotherapeutic pipeline and CNSide diagnostic platform.

Plus Therapeutics is urging its stockholders to vote on several critical proposals, including a reverse stock split, an increase in authorized shares, and warrant amendments, at a special virtual meeting on May 2, 2025.

Plus Therapeutics is holding a special meeting of stockholders to vote on proposals including a reverse stock split, authorization of warrant issuances, an increase in authorized common stock, and an extension of warrant terms.

Plus Therapeutics issues a supplement to its definitive proxy statement to clarify the number of shares available for grant under the 2015 New Employee Incentive Plan.

Plus Therapeutics is making strides in its targeted radiotherapeutic platform, seeking stockholder approval for an amended stock incentive plan to attract and retain key personnel.